Loading...

We've got a brand new version of Simply Wall St! Try it out

Bucephalus Capital

CNSX:BCA
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BCA
CNSX
CA$1M
Market Cap
  1. Home
  2. CA
  3. Diversified Financials
Company description

Bucephalus Capital Corp. provides various merchant banking services to micro and small-cap companies in North America. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Bucephalus Capital has significant price volatility in the past 3 months.
BCA Share Price and Events
7 Day Returns
-37.5%
CNSX:BCA
-0.8%
CA Diversified Financial
1.3%
CA Market
1 Year Returns
-28.6%
CNSX:BCA
36.8%
CA Diversified Financial
-0.1%
CA Market
BCA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bucephalus Capital (BCA) -37.5% 0% - -28.6% -28.6% -
CA Diversified Financial -0.8% 2.7% 7.5% 36.8% -33.3% -22.8%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • BCA underperformed the Diversified Financial industry which returned 36.8% over the past year.
  • BCA underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
BCA
Industry
5yr Volatility vs Market

Value

 Is Bucephalus Capital undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Bucephalus Capital. This is due to cash flow or dividend data being unavailable. The share price is CA$0.05.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bucephalus Capital's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bucephalus Capital's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:BCA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.02
CNSX:BCA Share Price ** CNSX (2019-09-16) in CAD CA$0.05
Canada Diversified Financial Industry PE Ratio Median Figure of 7 Publicly-Listed Diversified Financial Companies 9.8x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bucephalus Capital.

CNSX:BCA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:BCA Share Price ÷ EPS (both in CAD)

= 0.05 ÷ -0.02

-2.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bucephalus Capital is loss making, we can't compare its value to the CA Diversified Financial industry average.
  • Bucephalus Capital is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Bucephalus Capital's expected growth come at a high price?
Raw Data
CNSX:BCA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Diversified Financial Industry PEG Ratio Median Figure of 9 Publicly-Listed Diversified Financial Companies 0.6x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Bucephalus Capital, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Bucephalus Capital's assets?
Raw Data
CNSX:BCA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.04
CNSX:BCA Share Price * CNSX (2019-09-16) in CAD CA$0.05
Canada Diversified Financial Industry PB Ratio Median Figure of 13 Publicly-Listed Diversified Financial Companies 1.01x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:BCA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:BCA Share Price ÷ Book Value per Share (both in CAD)

= 0.05 ÷ 0.04

1.12x

* Primary Listing of Bucephalus Capital.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bucephalus Capital is overvalued based on assets compared to the CA Diversified Financial industry average.
X
Value checks
We assess Bucephalus Capital's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Diversified Financial industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Diversified Financial industry average (and greater than 0)? (1 check)
  5. Bucephalus Capital has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Bucephalus Capital expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bucephalus Capital has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.8%
Expected Diversified Financial industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bucephalus Capital expected to grow at an attractive rate?
  • Unable to compare Bucephalus Capital's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Bucephalus Capital's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Bucephalus Capital's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:BCA Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Diversified Financial Industry Earnings Growth Rate Market Cap Weighted Average 61.8%
North America Diversified Financial Industry Revenue Growth Rate Market Cap Weighted Average 4.2%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:BCA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:BCA Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 0 -1
2019-03-31 0 0 -1
2018-12-31 0 0 -1
2018-09-30 0 0 0
2018-06-30 0 0 0
2018-03-31 0 0 0
2017-12-31 0 0 0
2017-09-30 0 0 0
2017-06-30 0 -1 0
2017-03-31 0 0 0
2016-12-31 0 -1 -1
2016-09-30 0 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Bucephalus Capital is high growth as no earnings estimate data is available.
  • Unable to determine if Bucephalus Capital is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:BCA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Bucephalus Capital Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BCA Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.02
2019-03-31 -0.02
2018-12-31 -0.02
2018-09-30 -0.01
2018-06-30 0.00
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.02
2017-03-31 0.00
2016-12-31 -0.02
2016-09-30 -0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Bucephalus Capital will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Bucephalus Capital's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Bucephalus Capital's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Diversified Financials companies here
  3. Bucephalus Capital's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Bucephalus Capital's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the North America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bucephalus Capital has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Bucephalus Capital performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bucephalus Capital's growth in the last year to its industry (Diversified Financial).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bucephalus Capital does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Bucephalus Capital's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Bucephalus Capital's 1-year growth to the CA Diversified Financial industry average as it is not currently profitable.
Earnings and Revenue History
Bucephalus Capital's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bucephalus Capital Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BCA Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -0.17 -0.60 0.33
2019-03-31 -0.13 -0.55 0.33
2018-12-31 -0.24 -0.64 0.33
2018-09-30 0.16 -0.20 0.34
2018-06-30 0.36 0.03 0.33
2018-03-31 -0.04 -0.38 0.32
2017-12-31 0.21 -0.15 0.30
2017-09-30 0.06 -0.41 0.27
2017-06-30 0.01 -0.45 0.27
2017-03-31 0.46 -0.05 0.31
2016-12-31 -0.11 -0.63 0.31
2016-09-30 -0.48 -1.24 0.31
2016-06-30 -0.46 -1.13 0.25
2016-03-31 -0.50 -1.04 0.13
2015-12-31 -0.16 -0.58 0.08
2015-09-30 0.26 0.23 0.03
2015-03-31 0.26 0.19 0.06
2014-12-31 0.26 0.18 0.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Bucephalus Capital has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Bucephalus Capital has efficiently used its assets last year compared to the CA Diversified Financial industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Bucephalus Capital improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Bucephalus Capital's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Diversified Financial industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bucephalus Capital has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Bucephalus Capital's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bucephalus Capital's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bucephalus Capital is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bucephalus Capital has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bucephalus Capital's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Bucephalus Capital has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bucephalus Capital Company Filings, last reported 2 months ago.

CNSX:BCA Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 1.31 0.00 0.46
2019-03-31 1.44 0.00 0.50
2018-12-31 1.46 0.00 0.59
2018-09-30 1.62 0.00 0.71
2018-06-30 1.92 0.00 0.47
2018-03-31 1.99 0.00 0.58
2017-12-31 2.10 0.00 1.07
2017-09-30 1.82 0.00 0.61
2017-06-30 1.89 0.00 0.57
2017-03-31 2.30 0.00 1.09
2016-12-31 2.17 0.00 0.77
2016-09-30 2.16 0.00 0.67
2016-06-30 2.26 0.00 1.20
2016-03-31 2.31 0.09 0.66
2015-12-31 2.77 0.09 1.56
2015-09-30 3.25 0.00 0.19
2015-03-31 3.23 0.00
2014-12-31 3.23 0.00
  • Bucephalus Capital has no debt.
  • Bucephalus Capital currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Bucephalus Capital has sufficient cash runway for 1.7 years based on current free cash flow.
  • Bucephalus Capital has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of -29.3% each year.
X
Financial health checks
We assess Bucephalus Capital's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bucephalus Capital has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Bucephalus Capital's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Bucephalus Capital dividends.
If you bought CA$2,000 of Bucephalus Capital shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Bucephalus Capital's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Bucephalus Capital's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:BCA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Canada Diversified Financial Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 2%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Bucephalus Capital has not reported any payouts.
  • Unable to verify if Bucephalus Capital's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Bucephalus Capital's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Bucephalus Capital has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Bucephalus Capital's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bucephalus Capital afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bucephalus Capital has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Bucephalus Capital's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Lucas Ewart
AGE 44
TENURE AS CEO 1.6 years
CEO Bio

Mr. Lucas G. Ewart has been Chief Executive Officer and Director of Bucephalus Capital Corp. since February, 2018. Mr. Ewart has extensive experience in finance, senior management and corporate development of public and private companies. He has served as Chairman, CEO as well as Chief Restructuring Officer of numerous companies on an international scale having worked in Canada, USA, Australia, Mexico, and South East Asia (Hong Kong, Singapore, Philippines and China). In addition he served as a Principal to GC-Global Capital Corp. for 10 years which specialized in securitized bridge loans. He served as the Chairman of the Board and President of Bison Gold Exploration Inc. Mr. Ewart served as the Chief Executive Officer of Bison Gold Exploration Inc. since August 14, 2007 until July 2012. Mr. Ewart served as a Consultant of GC-Global Capital Corp., since 2005, where he managed the Investment Banking activities. He served as Vice President of Yoho Resources Inc. since June 2002. Mr. Ewart served as the Chief Executive Officer of E&E Capital Funding Inc., an affiliate of GC Global Capital Corp. since May 2005. He served as Research Analyst of Thomas Kernaghan & Company Ltd. Mr. Ewart was previously involved in many aspects of corporate and developmental finance with a number of brokerage firms and Investment banks in Australia, Canada and Europe. He served as the Chairman and Chief Executive Officer at Virgin Metals Inc. from August 2009 to June 24, 2010. Mr. Ewart has been Chairman of the Board of J.E.M. Capital Corporation since September 1997. He served as a Director for Bison Gold Exploration Inc. since August 2007. He served as a Director of NWM Mining Corporation from November 2006 to September 2010. Mr. Ewart served as a Director of Yoho Resources Inc., VoiceIQ Inc., Auspript PTY, Spark and Canon PTY from April 2002 to December 2004. He served as a Director of E&E Capital Funding Inc. since April 5, 2004. Mr. Ewart served as a Director of Virgin Metals Inc. since August 2009.

CEO Compensation
  • Insufficient data for Lucas to compare compensation growth.
  • Insufficient data for Lucas to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Jennifer Robb

TITLE
CFO & Corporate Secretary
COMPENSATION
CA$36K
TENURE
3.8 yrs

Lucas Ewart

TITLE
CEO, President & Director
AGE
44
TENURE
1.6 yrs
Board of Directors Tenure

Average tenure and age of the Bucephalus Capital board of directors in years:

3.8
Average Tenure
46
Average Age
  • The tenure for the Bucephalus Capital board of directors is about average.
Board of Directors

Lucas Ewart

TITLE
CEO, President & Director
AGE
44
TENURE
1.6 yrs

Jason Ewart

TITLE
Director
AGE
46
TENURE
3.8 yrs

Alec Regis

TITLE
Independent Director
AGE
46
TENURE
3.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Bucephalus Capital's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bucephalus Capital has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Bucephalus Capital Corp. provides various merchant banking services to micro and small-cap companies in North America. The company offers private and public companies with working capital in the form of common equity, preferred shares, convertible debt, and bridge loans across various industries, such as oil and gas, mining, real estate, manufacturing, retail, financial services, technology, and biotechnology. It is also involved in developing mergers and acquisitions, providing operational management support, and structuring and negotiating debt and equity placements. The company was formerly known as Bradstone Capital Corp. and changed its name to Bucephalus Capital Corp. in April 2019. The company is based in Toronto, Canada. Bucephalus Capital Corp. is a subsidiary of Fountain Asset Corp.

Details
Name: Bucephalus Capital Corp.
BCA
Exchange: CNSX
Founded:
CA$1,475,712
29,514,241
Website: http://www.bucephaluscapital.ca
Address: Bucephalus Capital Corp.
B2 - 125 The Queensway,
Suite 217,
Toronto,
Ontario, M8Y 1H6,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX BCA Subordinate Voting Shares Canadian National Stock Exchange CA CAD 14. Mar 2016
Number of employees
Current staff
Staff numbers
0
Bucephalus Capital employees.
Industry
Specialized Finance
Diversified Financials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:31
End of day share price update: 2019/09/16 00:00
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.